cbb 1
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2023 (NCT05832073)
Timeline
Indications
Studied for
Mechanism of action
- Lyssavirus rabiesINHIBITOR
Lyssavirus rabies inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06548139 | Phase 2 | Jul 31, 2024 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Government of China, Yunnan University of Traditional Chinese Medicine |
| NCT05832073 | Early Phase 1 (Phase 1) | Apr 30, 2023 | Anning City First People's Hospital, Changchun BCHT Biotechnology Co., Government of China, Yunnan University of Traditional Chinese Medicine |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anning City First People's Hospital | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Changchun BCHT Biotechnology Co. | For profit | 2 | 2 | 2 | 2023 |
| Government of China | Government | 2 | 0 | 2 | 2023 |
| Yunnan University of Traditional Chinese Medicine | Academic/Hospital | 2 | 0 | 2 | 2023 |
4 organizations
Page 1 / 1